Drug intelligence / Profile preview

LC-MG-5

Development stage: Unknown
Lead developer: Hangzhou Medical College

Overview

LC-MG-5: sourced facts only. name: "Preliminary screening and subsequent lead optimization identified LC-MG-5 and LC-MG-10 as highly efficient degraders of FGFR2." [PMID:42258945]; target: "Preliminary screening and subsequent lead optimization identified LC-MG-5 and LC-MG-10 as highly efficient degraders of FGFR2." [PMID:42258945]; developer: "Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China." [PMID:42258945]

Targets

FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on LC-MG-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC-MG-5.